On July 8, WuXi Biologics declined 3.05% in regular trading, trading at 35.62 HKD/share, with turnover of HKD 954 million. The decline was driven by broad-based weakness across the Life Sciences Tools and Services sector for a second consecutive session, with notable sector resonance effects.

On the news front, sector peers fell in tandem — WuXi AppTec dropped 3.33%, WuXi XDC fell 3.88%, GenScript Biotech declined 1.33%, and XtalPi lost 1.41%. The sustained sector sell-off followed a similarly weak session on July 7, when the broader life sciences group experienced declines of 3-4%. Despite the pullback, UBS recently raised its target price for WuXi Biologics to HKD 51.1 while maintaining a Buy rating, implying significant upside from current levels. The company has also maintained an aggressive buyback program, repurchasing 2.716 million shares on July 7 at prices between HKD 36.56 and HKD 36.88, spending approximately HKD 99.82 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)